“The thing that I worry about more than loss of exclusivity is this term that I introduced at the AACR meeting -- loss of relevancy" says Susan Galbraith, EVP of Oncology R&D at AstraZeneca. In this episode, Galbraith and David Fredrickson, EVP of Oncology Business Unit, join Bloomberg Intelligence analyst Sam Fazeli fresh from ASCO to discuss how AstraZeneca is navigating an increasingly complex oncology landscape. From a legacy in small molecules to a bold push into areas ranging from cell therapy to antibody-drug conjugates, they explain how the company aims to sustain growth and relevance. The discussion also covers new trial designs, biomarker-driven strategies, and why innovation, not exclusivity, is the true metric of success.

See omnystudio.com/listener for privacy information.